Quick Answer
Anixa Biosciences Inc reported Operating Income Loss of -$11.70 million for the year ending 2025.
- Anixa Biosciences Inc showed an increase of +15.4% in Operating Income Loss from 2024 to 2025.
- This data is from Anixa Biosciences Inc's annual report (Form 10-K), filed with the SEC on January 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$1.53 million | Q2 2011: -$1.29 million | Q3 2011: -$1.21 million | Q1 2012: -$887.3 thousand | Q2 2012: -$878.2 thousand | Q3 2012: -$643.3 thousand | Q1 2013: -$2.07 million | Q2 2013: -$1.85 million | Q3 2013: -$2.22 million | Q1 2014: -$1.96 million | Q2 2014: -$1.36 million | Q3 2014: -$159.6 thousand | Q1 2015: $3.86 million | Q2 2015: -$2.13 million | Q3 2015: -$1.49 million | Q1 2016: -$1.47 million | Q2 2016: -$1.15 million | Q3 2016: -$974.9 thousand | Q1 2017: -$1.39 million | Q2 2017: -$1.21 million | Q3 2017: -$1.73 million | Q1 2018: -$1.87 million | Q2 2018: -$1.40 million | Q3 2018: -$5.61 million | Q1 2019: -$4.98 million | Q2 2019: -$2.59 million | Q3 2019: -$2.18 million | Q1 2020: -$2.63 million | Q2 2020: -$2.67 million | Q3 2020: -$2.44 million | Q1 2021: -$2.23 million | Q2 2021: -$2.44 million | Q3 2021: -$4.39 million | Q1 2022: -$3.88 million | Q2 2022: -$3.59 million | Q3 2022: -$2.80 million | Q1 2023: -$2.56 million | Q2 2023: -$2.56 million | Q3 2023: -$2.84 million | Q1 2024: -$3.61 million | Q2 2024: -$3.47 million | Q3 2024: -$3.59 million | Q1 2025: -$3.39 million | Q2 2025: -$3.00 million | Q3 2025: -$2.44 million | Q1 2026: -$2.72 million.
- Over the full 16 years of available data (2010 to 2025), Anixa Biosciences Inc's Operating Income Loss has declined by 123.0%.
- Historical annual values: Fiscal year 2025: -$11.70 million | Fiscal year 2024: -$13.83 million | Fiscal year 2023: -$11.01 million | Fiscal year 2022: -$13.88 million | Fiscal year 2021: -$13.14 million | Fiscal year 2020: -$9.98 million | Fiscal year 2019: -$11.89 million | Fiscal year 2018: -$14.29 million | Fiscal year 2017: -$6.08 million | Fiscal year 2016: -$4.51 million | Fiscal year 2015: -$944.8 thousand | Fiscal year 2014: -$5.04 million | Fiscal year 2013: -$7.92 million | Fiscal year 2012: -$4.13 million | Fiscal year 2011: -$5.03 million | Fiscal year 2010: -$5.25 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: